IQVIA (IQV) Q2 2026 earnings review
Massive Bookings Rebound Vindicates Management, Drives Guidance Raise
IQVIA delivered a decisive Q2 performance that effectively neutralized investor fears stemming from Q1's anemic 1.04x book-to-bill ratio. The company posted a record $3.15B in R&D Solutions net new bookings, catapulting the book-to-bill to a Reversing and highly positive 1.22x. Revenue grew an Accelerating 8.7% YoY to $4.36B, while Adjusted EPS jumped 12.1% to $3.15. Pointing to a 'strengthening market environment,' management raised full-year guidance for Revenue, EBITDA, and EPS. However, the divergence between surging adjusted metrics and a 3.8% decline in GAAP Net Income warrants monitoring.
🐂 Bull Case
The Q1 bookings air pocket was a true anomaly. The 19% YoY surge in Q2 net new bookings ($3.15B) proves large pharma and EBP funding are flowing back into tangible clinical awards.
Commercial Solutions is hitting its stride, growing 8.6% organically. High-single-digit growth in consulting and double-digit growth in patient solutions demonstrate robust demand outside of pure clinical trials.
🐻 Bear Case
While Adjusted EPS jumped 12.1%, GAAP Net Income actually fell 3.8% YoY, dragged down by doubled restructuring costs ($63M) and a rising interest burden ($197M).
The 100 bps raise in organic revenue guidance is excellent, but management also baked in a 50 bps higher contribution from acquisitions to hit their new revenue target, indicating inorganic dependency.
⚖️ Verdict: 🟢
Bullish. Management promised that Q1's low bookings were a mix-related fluke, and Q2's record $3.15B performance thoroughly proved them right. With a 1.22x book-to-bill and raised EPS guidance, the fundamental growth engine is clearly Accelerating.
Key Themes
R&D Solutions Bookings Reversal
Following an intense defense of Q1's 1.04x book-to-bill ratio, management delivered a Reversing and definitive 1.22x in Q2. Net new bookings hit a record $3.15B, up 19% YoY. This directly converts to a massive $34.2B contracted backlog, with $9.2B expected to convert to revenue in the next twelve months (up 7.5% YoY), providing immense near-term visibility.
Commercial Solutions Hits its Stride
The simplified two-segment structure is highlighting the strength of the Commercial business. Commercial Solutions revenue accelerated 8.6% YoY to $1.79B, driven by double-digit growth in patient solutions and commercial engagement services. This proves the company is successfully capturing integrated outsourcing deals post-approval.
AI Adoption Propels Analytics Demand
IQVIA's narrative that AI is a demand-creator continues to materialize in the financials. Management specifically cited 'increased adoption of our AI solutions' and 'Healthcare-grade AI' as key contributors to the high-single-digit organic growth in Analytics and Consulting. Far from cannibalizing service revenue, AI is driving clients to invest heavily in data foundation modernization via IQVIA Connected Intelligence.
Strengthening Macro Backdrop
CEO Ari Bousbib explicitly noted a 'strengthening market environment.' After quarters of 'deliberate' and elongated client decision-making highlighted throughout 2025, the release of $3.15B in quarterly bookings signals an Accelerating macro recovery. Biopharma clients are officially moving off the sidelines.
GAAP to Non-GAAP Divergence Widens
A concerning break in trend: while Adjusted Net Income grew 12.1% to $527M, GAAP Net Income experienced a Decelerating trend, dropping 3.8% YoY to $256M. The culprits were non-operational but very real cash costs: Restructuring costs nearly doubled from $32M to $63M, and Interest Expense climbed from $182M to $197M. This contradiction between rosy adjusted metrics and shrinking statutory profit warrants scrutiny.
Guidance Leans on M&A Contribution
While the headline revenue guidance raise is optically strong (midpoint target moves from 5.8% to 6.5% growth), the composition has shifted. The new guidance assumes approximately 200 basis points of contribution from acquisitions, up from 150 basis points in the prior outlook. IQVIA is increasingly relying on inorganic bolt-ons to bolster its top-line trajectory.
Foreign Exchange Headwinds Mount
The currency environment has flipped to a net negative. Management noted an approximately 80 basis points unfavorable change in foreign exchange impact relative to their prior guidance. The updated guidance now assumes only a 20 basis point FX tailwind, down sharply from the 100 basis point tailwind projected just a quarter ago.
Other KPIs
Accelerating significantly. Up 26.0% YoY from Q2 2025's $443M, showcasing strong cash generation and excellent working capital management despite the massive surge in new bookings. Translates to $360M in Free Cash Flow (+23.3% YoY).
Stable capital return program. Brought first-half 2026 share repurchases to $950M. The company continues to lean on its massive $2.82B remaining authorization to drive EPS accretion, deploying roughly 110% of Q2 Free Cash Flow toward buybacks.
Stable. Total net debt sits at $14.09 billion. Despite heavy share repurchases and rising interest expenses, the ratio remains steady against the trailing twelve-month Adjusted EBITDA, well within the company's historical comfort zone.
Guidance
Accelerating. Raised from prior expectations. The new midpoint ($17.375B) implies 6.5% YoY growth over FY25's $16.31B, an improvement from the prior 5.8% assumption. This reflects 100 bps of higher organic growth and an extra 50 bps from M&A, partially offset by an 80 bps FX headwind.
Accelerating. Raised from prior guidance. The midpoint ($4.025B) implies approximately 6.3% YoY growth vs FY25's $3.788B, demonstrating operating leverage as higher-margin software/data assets and commercial solutions scale.
Accelerating. Raised from the Q1 guide. The midpoint ($12.90) represents ~8.2% YoY growth vs FY25's $11.92. Fueled by strong operational execution and aggressive share repurchases, offsetting the higher interest expense burden.
Key Questions
Bookings Mix and Margins
In Q1, you noted the low book-to-bill was driven by an unusual mix of trials with low pass-throughs. With Q2 bookings surging to $3.15B, has the mix reverted to historic norms, and how does this quarter's specific pass-through profile impact forward margin expectations?
Restructuring Cost Acceleration
GAAP Net Income declined year-over-year largely due to restructuring costs doubling to $63 million in the quarter. What specific operational footprints or geographies are being targeted with these elevated cash costs, and when will we see the resulting run-rate savings?
M&A Strategy Shift
The updated revenue guidance assumes 200 basis points of growth from acquisitions, up from 150 basis points. Are you seeing more attractive valuations for bolt-on assets in the Commercial/Data space, and will these acquisitions be margin-accretive in their first full year of integration?